Stanford trial points to a new CAR-T drug, spotlighting a fresh target for next-gen cell therapies
CAR-T researchers have had years to study CD19 protein molecules as a target in their successful leukemia studies. But a small, exploratory study at Stanford …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
